Analytical Data
-
Gene name
EIF1AX
- Application
-
Alternative Names
EIF1AX；EIF1A；EIF4C;Eukaryotic translation initiation factor 1A. X-chromosomal
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P47813
-
Expression Region
1-144aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MPKNKGKGGK NRRRGKNENE SEKRELVFKE DGQEYAQVIK MLGNGRLEAM CFDGVKRLCH IRGKLRKKVW INTSDIILVG LRDYQDNKAD VILKYNADEA RSLKAYGELP EHAKINETDT FGPGDDDEIQ FDDIGDDDED IDDI
-
Molecular Weight
19 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EIF1AX, or Eukaryotic Translation Initiation Factor 1A, plays a crucial role in the process of translation initiation in eukaryotic cells. Recent studies have highlighted its involvement in various cellular processes and its potential implications in cancer biology. Research has shown that mutations in the EIF1AX gene can lead to aberrant protein synthesis, which is associated with several types of malignancies, including melanoma and glioma. The identification of these mutations has sparked interest in using EIF1AX as a potential biomarker for cancer diagnosis and prognosis. Moreover, the study of EIF1AX recombinant proteins has opened up new avenues for understanding the molecular mechanisms underlying its function and regulation in translation. By producing and characterizing EIF1AX recombinant proteins, researchers aim to elucidate its interactions with other translation factors and RNA, as well as its role in the ribosomal assembly process. This research is significant not only for cancer biology but also for the broader understanding of gene expression regulation at the translational level. Given the potential of EIF1AX in therapeutic target identification, ongoing investigations into its recombinant protein structure and functionality are essential for the development of novel cancer treatment strategies.
